Skip to main content
SpringerLink
Log in

Strategies for Global Prevention of Hepatitis B Virus Infection

  • Chapter
  • First Online:
Hot Topics in Infection and Immunity in Children VI

Part of the book series: Advances in Experimental Medicine and Biology ((AEMB,volume 659))

Abstract

HBV is a double-stranded, enveloped virus of the Hepadnaviridae family. The Hepadna virus family has the smallest genome of all replication competent animal DNA viruses. The single most important member of the family is HBV. Eight genotypes of HBV have been identified; they have been termed A-H. These genotypes are associated with a particular geographic distribution: genotype A being most common in the United States and Northern Europe, B and C in Asia, and D in Mediterranean countries and the Middle East (Table ). he association of HBV genotypes with different clinical outcome and response to interferon has been described: chronic infection with genotype B appears to have a better prognosis than genotype C. Pre-core mutant infection is also most common in genotypes B, C and D, which explains why pre-core mutant infection is more common in Asia and Southern Europe. Further research is currently being performed on the role of these genotypes in transmission, disease pattern, and response to therapy

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Banatvala, J.E., & Van Damme, P. (2003). Hepatitis B vaccine-do we need boosters? J Hepatol, (10), 1–6.

    CAS  Google Scholar 

  • Banatvala, J.E., Van Damme, P., & Emiroglu, N. (2006). Hepatitis B immunization in Britain: time to change? BMJ, (332), 804–805.

    Article  PubMed  Google Scholar 

  • Bonanni, P., Pesavento, G., Bechini, A., Tiscione, E., Mannelli, F., Benucci, C., & Nostro, A.L. (2003). Impact of universal vaccination programmes on the epidemiology of hepatitis B: 10 years of experience in Italy. Vaccine, (21), 685–691.

    Article  PubMed  Google Scholar 

  • Centers for Disease Control and Prevention 1987 (1987). Recommendations of the immunization practices advisory committee. Update on hepatitis B prevention. Morbid Mortal Weekly Report, (36), 353–360.

    Google Scholar 

  • Chan, C.Y., Lee, S.D., & Lo, K.J. (2004). Legend of hepatitis B vaccination: the Taiwanese experience. J Gastroenterol Hepatol, (19), 121–126.

    Article  PubMed  Google Scholar 

  • Chen, C.-J., Yang, H.-I., Su, J., Jen, C.-L., You, S.-L., Lu, S.-N., Huang, G.-T. et al. (2006). Risk of HCC across a biological gradient of serum HBV-DNA levels. JAMA, (295), 65–73.

    Article  PubMed  CAS  Google Scholar 

  • Coursaget, P., Leboulleux, D., Soumare, M., le Cann, P., Yvonnet, B., Chiron, J.P. et al. (1994). Twelve-year follow-up study of hepatitis B immunisation of Senegalese infants. J Hepatol, (21), 250–254.

    Article  PubMed  CAS  Google Scholar 

  • Da Villa, G., Romanò, L., Sepe, A., Iorio, R., Parimbello, N., Zappa, A., & Zanetti, A.R. (2007). Impact of hepatitis B vaccination in high endemic area of south Italy and long-term duration of anti-HBs antibody in two cohort of vaccinated individuals. Vaccine, (25), 3133–3136.

    Article  PubMed  Google Scholar 

  • Dienstag, J.L., Werner, B.G., Polk, B.F., Snydman, D.R., Craven, D.E., & Platt, R. (1984). Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med, (82), 8168–8172.

    Google Scholar 

  • Duclos, P. (2003). Safety of immunization and adverse events following vaccination against hepatitis B. J Hepatol, (39), 83–88.

    Article  Google Scholar 

  • EUROHEP.NET (2004). Data on surveillance and prevention of hepatitis A and B in 22 countries, 1990–2001. Antwerp; (also available on http://www.eurohep.net)

  • European Consensus Group on Hepatitis B immunity (2000). Are booster immunisations needed for lifelong hepatitis B immunity? Lancet, (355), 561–565.

    Article  Google Scholar 

  • Erhardt, A., Blondin, D., Hauck, K., Sagir, A., Kohnle, T., Heintges, T., & Häussinger, D. (2005). Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D. Gut, (54), 1009–1013.

    Article  PubMed  CAS  Google Scholar 

  • Francois, G., Hallauer, J., & Van Damme, P. (2002). Hepatitis B vaccination: how to reach risk groups. Vaccine, (21), 1–4.

    Article  PubMed  Google Scholar 

  • Gaeta, G.B., Stroffolini, T., Chiaramonte, M., Ascione, T., Stornaiuolo, G., Lobello, S., Sagnelli, E. et al. (2000). Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology, (32), 824–827.

    Article  PubMed  CAS  Google Scholar 

  • Goldstein, S.T., Zhou, F., Hadler, S.C., Bell, B.P., Mast, E.E., & Margolis, H.S. (2005). A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol, (34), 1329–1339. Available at: http://aim.path.org/en/vaccines/hepb/assessBurden/model/index.html (retrieved on 3 October 2008).

    Article  PubMed  Google Scholar 

  • Hadler, S.C. & Margolis, H.S. (1992). Hepatitis B immunization: vaccine types, efficacy, and indications for immunization. In: Topics In Infectious Diseases. J.S. Remington, & M.N. Swartz (Eds.). (Vol. 12). Boston: Blackwell Scientific Publications, pp. 282–308.

    Google Scholar 

  • Hahné, S., Ramsay, M., Balogun, K., Edmunds, W.J., & Mortimer, P. (2004). Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995–2000: implications for immunisation policy. J Clin Virol, (29), 211–220.

    Article  PubMed  Google Scholar 

  • Hollinger, F.B. (1989). Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines and vaccine protocol recommendations. Am J Med, 87(Suppl 3A), 36–40.

    Article  Google Scholar 

  • Jilg, W., Schmidt, M., Zachoval, R., & Deinhardt, F. (1984). Hepatitis B vaccination: how long does protection last? Lancet, (2), 458.

    Article  PubMed  CAS  Google Scholar 

  • Jilg, W., Schmidt, M., & Deinhardt, F. (1988). Persistence of specific antibodies after hepatitis B vaccination. J Hepatol, (6), 201–207.

    Article  PubMed  CAS  Google Scholar 

  • Kao, J.-H. & Chen, D.S. (2005). Hepatitis B vaccination: to boost or not to boost? Lancet, (366), 1337–1338.

    Article  PubMed  Google Scholar 

  • Keating, G.M. & Noble, S. (2003). Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs, (63), 1021–1051.

    Article  PubMed  CAS  Google Scholar 

  • Kretzschmar, M. & de Wit, A. (2008). Universal hepatitis B vaccination. Lancet, (8), 85–87.

    Article  Google Scholar 

  • Lavanchy, D. (2004). Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat, (11), 97–107.

    Article  PubMed  CAS  Google Scholar 

  • Lavanchy, D. (2005). Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. J Clin Virol, 34(Suppl 1), 1–3.

    Article  Google Scholar 

  • Lok, A.S.F. & McMahon, B.J. (2007). Chronic hepatitis B: AASLD practice guidelines. Hepatology, (45), 507–539.

    Article  PubMed  CAS  Google Scholar 

  • Mahoney, F.J. (1999). Update on diagnosis, management and prevention of hepatitis B virus infection. Clin Microbiol Rev, (12), 351–366.

    PubMed  CAS  Google Scholar 

  • Ng, K.P., Saw, T.L., Baki, A., Rozainah, K., Pang, K.W., & Ramanathan, M. (2005). Impact of expanded programme on immunization against hepatitis B infection in school children in Malaysia. Med Microbiol Immunol, (194), 163–168.

    Article  PubMed  CAS  Google Scholar 

  • Niu, M.T. (1996). Review of 12 million doses shows hepatitis B vaccine safe. Vaccine Weekly, (4), 13–15.

    Google Scholar 

  • Perz, J.F., Elm, J.L., Jr., Fiore, A.E., Huggler, J.I., Kuhnert, W.L., & Effler, P.V. (2006). Near elimination of hepatitis B infections among Hawaii elementary school children universal infant hepatitis B vaccination. Pediatrics, (118), 1403–1408.

    Article  PubMed  Google Scholar 

  • Piazza, M., Da Villa, G., Picciotto, L., Abrescia, N., Guadagnino, V., Memoli, A.M., Vegnente, A. et al. (1988). Mass vaccination against hepatitis B in infants in Italy. Lancet, (332), 1132.

    Article  Google Scholar 

  • Pollard, A.J. (2007). Hepatitis B vaccination. BMJ, (335), 950.

    Article  PubMed  Google Scholar 

  • Rendi-Wagner, P., Shouval, D., Genton, B., Lurie, Y., Rumke, H., Boland, G., Cerny, A. et al. (2006). Comparative immunogenicity of a PreS/S hepatitis B vaccine in non- and low responders to conventional vaccine. Vaccine, (24), 2781–2789.

    Article  PubMed  CAS  Google Scholar 

  • Romanò, L., Mele, A., Pariani, E., Zappa, A., & Zanetti, A. (2004). Update in the universal vaccination against hepatitis B in Italy: 12 years after its implementation. Eur J Public Health, 14(Suppl), S19.

    Google Scholar 

  • Safary, A. & André, F. (1999). Over a decade of experience with the yeast recombinant hepatitis B vaccine. Vaccine, (18), 57–67.

    Article  Google Scholar 

  • Shaefer, S. (2005). Hepatitis B virus: significance of genotypes. J Viral Hepat, (12), 111–124.

    Article  Google Scholar 

  • Shepard, E.W., Simard, E.P., Finelli, L., Fiore, A.E., & Bell, B.P. (2006). Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev, (28), 112–125.

    Article  PubMed  Google Scholar 

  • Sherlock, S. (1993). Clinical features of hepatitis. In: Viral Hepatitis. A.J. Zuckerman, H.S. Thomas (Eds.). London: Churchill Livingstone, pp. 1–11.

    Google Scholar 

  • Shouval, D., Ilan, Y., Adler, R., Deepen, R., Panet, A., Even-Chen, Z., Gorecki, M. et al. (1994). Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine, (12), 1453–1459.

    Article  PubMed  CAS  Google Scholar 

  • Szmuness, W., Stevens, C.E., Zang, E.A., Harley, E.J., & Kneller, A. (1981). A controlled clinical trial of the efficacy of the hepatitis B vaccine (Hepatavax B): a final report. Hepatology, (5), 377–385.

    Google Scholar 

  • Tan, J. & Lok, A.S.F. (2007). Update on viral hepatitis: 2006. Gastroenterology, (23), 263–267.

    CAS  Google Scholar 

  • Tandon, B.N. & Tandon, A. (1997). Epidemiological trends of viral hepatitis in Asia. In: Viral Hepatitis and Liver Disease. M. Rizzetto, R.H. Purcell, J.L. Gerin, & G. Verme (Eds.). Turin: Edizioni Minerva Medica, pp. 559–661.

    Google Scholar 

  • Tilson, L., Thornton, L., O’Flanagan, D., Johnson, H., & Barry, M. (2008). Cost-effectiveness of hepatitis B vaccination strategies in Ireland: an economic evaluation. Eur J Public Health, 18(3), 275–282.

    Article  PubMed  Google Scholar 

  • Van Damme, P., Kane, M., & Meheus, A. (1997). Integration of hepatitis B vaccination into national immunisation programmes. BMJ, (314), 1033–1037.

    PubMed  Google Scholar 

  • Van Damme, P., Van Herck, K., Leuridan, E., & Vorsters, A. (2004). Introducing universal hepatitis B vaccination in Europe: differences still remain between countries. Eurosurveillance Weekly, (9), 67–68.

    Google Scholar 

  • Van Damme, P. & Van Herck, K. (2007). A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis, (5), 79–84.

    Article  PubMed  Google Scholar 

  • van der Eijk, A.A., Niesters, H.G.M., Götz, H.M., Janssen, H.L.A., Schalm, S.W., Osterhaus, A.D.M.E., & de Man, R.A. (2004). Paired measurements of quantitative hepatitis B virus DNA in saliva and serum of chronic hepatitis B patients: implications for saliva as infectious agent. J Clin Virol, (29), 92–94.

    Article  PubMed  Google Scholar 

  • van Houdt, R., Sonder, G.J., Dukers, N.H., Bovee, L.P., van den Hoek, A., Coutinho, R.A., & Bruisten, S.M. (2007). Impact of targeted hepatitis B vaccination program in Amsterdam, the Netherlands. Vaccine, (25), 2698–2705.

    Article  PubMed  Google Scholar 

  • Venters, C., Graham, W., & Cassidy, W. (2004). Recombivax-HB: perspectives past, present and future. Expert Rev Vaccines, (3), 119–129.

    Article  PubMed  CAS  Google Scholar 

  • Viviani, S., Jack, A., Hall, A.J., Maine, N., Mendy, M., Montesano, R., & Whittle, H.C. (1999). Hepatitis B vaccination in infancy in the Gambia: protection against carriage at 9 years of age. Vaccine, (17), 2946–2950.

    Article  PubMed  CAS  Google Scholar 

  • Wainwright, R., Bulkow, L.R., Parkinson, A.J., Zanis, C., & McMahon, B.J. (1997). Protection provided by hepatitis B vaccine in a Yupik Eskimo Population: results of a 10 year study. J Infect Dis, (175), 674–677.

    PubMed  CAS  Google Scholar 

  • West, D.J. & Calandra, G.B. (1996). Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine, (14), 1019–1027.

    Article  PubMed  CAS  Google Scholar 

  • Whittle, H.C., Maine, N., Pilkington, J., Mendy, M., Fortuin, M., Bunn, J., Allison, L. et al. (1995). Long-term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet, (345), 1089–1092.

    Article  PubMed  CAS  Google Scholar 

  • World Health Organization 1992. (1992). Informal consultation on quadrivalent diphtheria-tetanus-pertussis-hepatitis B vaccine. Final Report, pp.1–12, Geneva.

    Google Scholar 

  • World Health Organization (2004). Hepatitis B vaccines (WHO position paper). Weekly Epidemiol Record, (79), 255–263.

    Google Scholar 

  • World Health Organization 2006. Vaccines and biologicals. WHO vaccine preventable disease monitoring system. Global summary 2006 (data up to 2005). Available at http://www.who.int/vaccines-documents/GlobalSummary.pdf (retrieved on 15 September 2007).

  • Zanetti, A.R., Tanzi, E., Romanò, L., & Grappasonni, I. (1993). Vaccination against hepatitis B: the Italian strategy. Vaccine, (11), 521–524.

    Article  PubMed  CAS  Google Scholar 

  • Zanetti, A.R., Mariano, A., Romanò, L., D’Amelio, R., Chironna, M., Coppola, R.C., Cuccia, M., Mangione, R., Marrone, F., Negrone, F.S., Parlato, A., Zamparo, E., Zotti, C., Stroffolini, T., & Mele, A; Study Group. (2005). Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet, 366(9494), 1379–1384.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Faculty of Medicine, Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium

    Pierre Van Damme & Koen Van Herck

  2. Faculty of Medicine, Department of Public Health-Microbiology-Virology, University of Milan, Milan, Italy

    Alessandro R. Zanetti

  3. Department of Medicine, Liver Unit, Hadassah-Hebrew University Hospital Jerusalem, Jerusalem, Israel

    Daniel Shouval

  4. 4Research Foundation – Flanders (FWO), Brussels, Belgium

    Koen Van Herck

Authors
  1. Pierre Van Damme
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro R. Zanetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Daniel Shouval
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Koen Van Herck
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Pierre Van Damme .

Editor information

Editors and Affiliations

  1. Institute of Child Life and Health, University of Bristol, Upper Maudlin Street, Bristol, BS2 8AE, United Kingdom

    Adam Finn

  2. Royal Children's Hosp., University of Melbourne, Parkville , 3052, Australia

    Nigel Curtis

  3. University of Oxford, Level 4,John Radcliffe Hospital, Oxford, OX3 9DU, United Kingdom

    Andrew J. Pollard

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Van Damme, P., Zanetti, A.R., Shouval, D., Van Herck, K. (2010). Strategies for Global Prevention of Hepatitis B Virus Infection. In: Finn, A., Curtis, N., Pollard, A. (eds) Hot Topics in Infection and Immunity in Children VI. Advances in Experimental Medicine and Biology, vol 659. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0981-7_14

Download citation

Publish with us

Policies and ethics

Search

Navigation